Role of Amritadi Kwath and Katukiadi Kwath in the treatment of Vatarakta.

INTERVENTION: CONDITION: Health Condition 1: M100‐ Idiopathic gout PRIMARY OUTCOME: Change in Serum Uric Acid in mg per dl and improvement in clinical parameters of Vatarakta such as Pain, Joint Swelling, Stiffness and Erythema.Timepoint: Assessed at Baseline Day 0, 1st week Day 7, 4th week Day 28, and 8th week Day 56 to 60. SECONDARY OUTCOME: Change in serum uric acid levels from baseline to end of treatment. ; ; Change in ESR Erythrocyte Sedimentation rate from baseline to end of treatment. ; ; Individual changes in the remaining subjective parameters such as Daha, Sparshasahatva, Shotha, Walking ability. ; ; Clinical safety and tolerability of both formulations incidence of adverse events or side effects. ; ; Timepoint: Uric acid level change Baseline Day 0 and 8th week end of treatment ; ; ESR Baseline Day 0 and 8th week end of treatment. ; ; Change subjective parameters Baseline Day 0, 1st week, 4th week, 8th week. ; ; Clinical safety and tolerability adverse events or side effects Continuously monitored throughout the study and specifically assessed at 1st week, 4th week, and 8th week follow ups. ; INCLUSION CRITERIA: 1. Patients having age 18 to 60 years of either se Xwill be selected for the study. 2. Classical sign and symptoms Ruja, Daha, Shoth, Sparshasahatva, will be included. 3. Patients having serum Uric acid according to WHO greater than 7.0 mg per dl in male and above 6.0 mg per dl in women. 4. Those patients who will be ready to give informed consent.